Home＞REGULATORY
Harvoni, Sovaldi under Review for Risks of Hypertension, Cerebrovascular Disorder(Jun.13.2016)
The Pharmaceuticals and Medical Devices Agency (PMDA) said on June 10 that it is reviewing the risks of hypertension and cerebrovascular disorder for hepatitis C drugs Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir), a move that is likely to result ...
(LOG IN FOR FULL STORY)
-
- Japan Cabinet Adopts 2018 Honebuto Policy, Inscribes Possible HTA Use in New Drug Listing Jun.18
- Authorized Generics for Aimix, Cravit IV Join NHI Price List Jun.15
-
Chuikyo Agrees on No Willing-to-Pay Cost Survey before CEA Rollout; Experts Say Pilot ICER Thresholds “Justifiable”
Jun.14
- Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks Jun.14
- Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib Jun.13
- Don’t Make Coverage Decision on CEA, Tweak Prices with Limited Scope: FPMAJ(Jun.18)
- Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group(Jun.18)
- Japan Cabinet Adopts 2018 Honebuto Policy, Inscribes Possible HTA Use in New Drug Listing(Jun.18)
- FPMAJ Welcomes Chuikyo’s Openness to Views of Experts on CEA: Drug Pricing Committee Chair(Jun.18)
- Atsushi Kamide of Astellas Elected as New Chairman of FPMAJ’s Drug Pricing Committee(Jun.18)
